Vaxart (NASDAQ: VXRT) is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing oral recombinant protein vaccines and therapeutics using its proprietary VAAST (Vaxart Adjuvant System Technology) platform. Founded in 2007, the company is pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases, offering a potentially revolutionary advance in immunization technology[@vaxart].
Funding
IPO: 2020 (NASDAQ: VXRT)
Market Cap: ~$100M
Mission
From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases. The company aims to create safe, effective, and accessible solutions that protect communities worldwide.
Technology Platform
VAAST (Vaxart Adjuvant System Technology)
Vaxart's oral pill vaccines leverage proprietary technology with several key advantages:
| Feature | Benefit | |---------|---------| | Oral delivery | Tablet form factor eliminating needles | | Room temperature stability | Enhanced logistics and storage capabilities | | Mucosal immunity | Stimulates IgA antibodies in respiratory and gut tracts | | Systemic immunity | Generates protective circulating antibodies | | Patient compliance | No injection required |
Platform Advantages
...
Overview
Vaxart (NASDAQ: VXRT) is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing oral recombinant protein vaccines and therapeutics using its proprietary VAAST (Vaxart Adjuvant System Technology) platform. Founded in 2007, the company is pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases, offering a potentially revolutionary advance in immunization technology[@vaxart].
Funding
IPO: 2020 (NASDAQ: VXRT)
Market Cap: ~$100M
Mission
From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases. The company aims to create safe, effective, and accessible solutions that protect communities worldwide.
Technology Platform
VAAST (Vaxart Adjuvant System Technology)
Vaxart's oral pill vaccines leverage proprietary technology with several key advantages:
| Feature | Benefit | |---------|---------| | Oral delivery | Tablet form factor eliminating needles | | Room temperature stability | Enhanced logistics and storage capabilities | | Mucosal immunity | Stimulates IgA antibodies in respiratory and gut tracts | | Systemic immunity | Generates protective circulating antibodies | | Patient compliance | No injection required |
Platform Advantages
No cold chain required: Simplified distribution and storage
Easy administration: Can be taken at home as a tablet
Broad immune response: Activates both mucosal (first-line) and systemic (circulating) immune defenses
Manufacturing efficiency: Recombinant protein production is scalable and cost-effective
Pipeline Programs
| Product | Indication | Development Phase | |---------|------------|-------------------| | COVID-19 Vaccine | SARS-CoV-2 prevention | Clinical development | | Norovirus Vaccine | Norovirus prevention | Clinical development | | Influenza Vaccine | Flu prevention | Clinical development | | HPV Vaccine | Human papillomavirus | Preclinical | | Alzheimer's Vaccine | Amyloid-beta targeting | Research |
COVID-19 Vaccine
Vaxart's oral COVID-19 vaccine candidate leverages the VAAST platform to generate mucosal and systemic immunity against SARS-CoV-2. The oral delivery approach may offer advantages in generating immunity at the primary site of viral entry (the respiratory tract).
Norovirus Vaccine
Norovirus is a leading cause of acute gastroenteritis worldwide. Vaxart's oral norovirus vaccine aims to generate mucosal immunity in the gut, the primary site of norovirus infection.
Influenza Vaccine
Seasonal flu remains a significant public health burden. Vaxart's oral influenza vaccine candidate is designed to generate broad protection against multiple flu strains.
Alzheimer's Disease Vaccine Program
Vaxart has been developing an oral amyloid-beta vaccine candidate for Alzheimer's disease. The oral delivery approach aims to generate immune responses against amyloid-beta plaques while potentially improving safety profile compared to injectable antibodies[@clinicaltrialsgov].
Key aspects of the Alzheimer's vaccine program:
Target: Amyloid-beta plaques — a key pathological hallmark of Alzheimer's disease
Approach: Oral delivery to generate mucosal immunity against Aβ
Advantage: Potential for improved safety and tolerability compared to intravenous immunotherapy
Corporate Information
| Item | Detail | |------|--------| | Headquarters | South San Francisco, California | | Founded | 2007 | | Stock exchange | NASDAQ | | Ticker symbol | VXRT | | Focus | Oral vaccines and therapeutics |
Recent Developments (2026)
March 2026: Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
March 2026: Vaxart to Host Upcoming Conference Calls
February 2026: Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Strategic Partnerships
Vaxart maintains partnerships to accelerate development of their pipeline:
Manufacturing partnerships for clinical supply
Academic collaborations for platform optimization
Government and non-governmental organizations for global health applications